Activities and concentration of alpha-1 antitrypsin and cystatin C in serum from patients with house dust mite asthma Authors: Mailani Dwi Hidayati, Febriana Catur Iswanti, Samsuridjal Djauzi, Sukamto Koesnoe, Mohamad Sadikin Published: 2023 ABSTRACT Background:The proteolytic activities of house dust mite (HDM) allergens are involved in the pathogenesis of asthma by cleaving T-junction protein complexes, increasing the permeability of airway epithelial cells, and enabling the allergens to reach the interstitial tissue. The human body contains natural protease inhibitors such as alpha-1 antitrypsin (AAT) with antiserine protease activity and cystatin C with anticysteine protease activity.Objective:This study aimed to investigate the behavior of serum AAT and cystatin C levels in patients with HDM-allergic asthma.Methods:Ten individuals with HDM-allergic asthma and 10 healthy volunteers participated in a cross-sectional study. The serum AAT and cystatin C inhibitory activities were measured using enzymatic assays. ELISA was used to determine the serum AAT and cystatin C concentrations.Results:Serum AAT inhibitory activity (P = 0.445; P > 0.05), AAT concentration (P = 0.290; P > 0.05), and cystatin C concentration (P = 0.419; P > 0.05) did not significantly differ between the patient and control groups. However, serum cystatin C inhibitory activity in the asthmatic patient group was significantly higher than in the healthy subjects (P = 0.001; P < 0.05). There was no correlation between AAT inhibitory activity and AAT concentration or between cystatin C inhibitory activity and cystatin C concentration.Conclusion:These findings suggest that serum cystatin C activity is involved in asthma pathogenesis. Additional research is required to address this issue. 1. Introduction Asthma is a noncommunicable disease characterized by repeated attacks of shortness of breath and wheezing, with varying degrees of severity and frequency among individuals [1]. Asthma is commonly observed in children. According to the 2018 RISKESDAS (Basic Health Research) national report, the prevalence of asthma in Indonesia was 2.4% [2]. According to the WHO, in 2019, approximately 262 million individuals worldwide were estimated to suffer from asthma. Moreover, 455,000 individuals died from asthma. Asthmatic deaths are most common among the elderly. Compared to other chronic diseases, the mortality rate due to asthma is relatively low. However, asthma limits an individual’s life activities [3]. The pathogenesis of asthma involves complex interactions between genetic and environmental factors [4]. More than 100 genes are known to be responsible for asthma, and several polymorphisms are involved. However, none of these genes can predict when an asthma attack will occur [5]. Environmental factors play an essential role in the development of asthma. Air pollution, cigarette smoke, outdoor allergens such as pollen, and indoor allergens such as mites can cause sensitization, which triggers asthma [6, 7]. House dust mites (HDM) produce enzymes that digest food from loose human skin cells, fungi, bacteria, and organic detritus. Enzymes accumulate in feces, which are found on mattresses, carpets, and furniture surfaces [8]. HDM can enter the respiration tract by aspiration air, attach epithelial cells to it, and reject feces containing digestive enzymes on the respiration tract surface [9]. Der p 1 is the major allergen of the HDM Dermatophagoides pteronyssinus and has cysteine protease activity that can cleave the claudin-1 protein at tight junctions (TJ) [10, 11]. A study in rats showed that the cysteine protease activity of Der p 1 increased the permeability of epithelial cells in the respiratory tract [12]. Der p 1 can activate other allergens, namely Der p 3, Der p 6, and Der p 9, which have serine protease activity [13]. A study using cell cultures exposed to Der p 3, Der p 6, and Der p 9 allergens with serine protease activity showed that occludin protein and zoluna occludens protein in TJ were cleaved [14]. The cleavage of TJ proteins between epithelial cells allows HDM allergens to access the immune cells [15]. The human body contains antiproteases that can deactivate allergenic proteases [16]. Alpha-1 antitrypsin (AAT) is a serine protease inhibitor. AAT is the most abundant inhibitory protein in plasma. Hepatocytes, alveolar epithelial cells, bronchial epithelial cells, intestinal epithelial cells, pancreatic Langerhans cells, monocytes, and macrophages produce AAT [17]. AAT is an active-phase protein involved in the resolution of inflammation [18]. In addition, the human body contains the cysteine protease inhibitor cystatin C [19]. All nucleated cells constitutively produce cystatin C, which is found in all body fluids [20]. In addition to acting as an antiprotease, cystatin C is consistent with several inflammatory markers, such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein [21]. AAT and cystatin C levels may be related to an individual’s tendency to develop asthma, which is triggered by exposure to HDM allergens. However, there have been no reports on the simultaneous measurement of AAT and cystatin C activity and concentration in individuals with asthma induced by HDM allergen exposure compared with healthy individuals. Therefore, in this study, the activity and concentrations of AAT and cystatin C were measured in the serum of patients with HDM-allergic asthma and healthy individuals. 2. Methods 2.1. Subjects and ethical statements The cross-sectional study was conducted at the Laboratory of Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Indonesia. Ten healthy subjects and 10 patients with HDM-allergic asthma participated in this study. Healthy control subjects were defined as subjects with no history of asthma, allergies to HDM, or symptoms. When recruited, vital signs (blood pressure, temperature, pulse, and respiration) were normal. No symptoms of fever or infection were observed. Patients with HDM-allergic asthma were recruited from the Allergy and Immunology Polyclinic, Department of Internal Medicine, Faculty of Medicine, the University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Patients with HDM-allergic asthma had specific anti-HDM IgE levels of 0.35 kU/L or more. Blood was collected during the outpatient visit to the allergy clinic. Subjects with a history of smoking, kidney disease, hypertension, diabetes mellitus, heart disease, and cancer were excluded from this study. Ethical approval for this study (KET594/UN2.F1/ETIK/PPM.00.02/2021) was provided by the Ethical Committee of the Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia (Chairperson, Prof. Rita Sita Sitorus, Ph.D.) on June 14, 2021. All the participants provided informed consent. 2.2. Serum collection Five milliliters of blood were collected from the cubital vein using an anticoagulant-free tube. The blood was then incubated at room temperature for 20 min, and then centrifuged at 4°C for 10 min at 3,000 rpm. The serum was separated and stored at −20°C until analysis. 2.3. Alpha-1 antitrypsin inhibitory activity assay The inhibitory activity assay was performed in the presence or absence of serum during the catalytic process of trypsin in the casein substrate, as described by Crawford et al. [22] and Merck [23], with modifications. Trypsin digests casein and releases the amino acid tyrosine. The absorption of tyrosine was evaluated at 280 nm using a spectrophotometer. Bovine serum albumin (BSA) (Sigma-Aldrich A7030; Merck KGaA, Darmstadt, Germany) in several concentrations (0.025, 0.05, 0.1, 0.2, 0.4, and 0.8 mg/mL) was set as a standard curve for tyrosine release. The reaction mixture (70 µL) consisted of 20 µL trypsin solution (1 mg/mL) (Sigma-Aldrich T1426) and 50 µL serum (diluted 100 times with ddH2O) or BSA (40 mg/mL) (diluted 100 times with ddH2O). The reaction mixtures were incubated at 37°C for 10 min. Casein substrate (0.2%, 750 µL) (Sigma-Aldrich C-4765) was added to the tubes and incubated at 37°C for 10 min. Tri chloroacetic acid 0.11 M (750 µL) (Sigma-Aldrich 76-03-9) was added to each tube. Another incubation at 37°C for 30 min was performed to complete precipitation. After centrifugation at 10.000 rpm for 15 min, absorbance was measured at 280 nm. The absorbance of the reaction mixture was converted to the amount of tyrosine released using a standard curve. The antitrypsin activity was calculated using the following formula: Total volume (in milliliters) of assay. Total volume (in milliliters) of assay. Volume of enzyme (in milliliters) of enzyme used. Volume of enzyme (in milliliters) of enzyme used. Time of assay (in min) as per the unit definition. Time of assay (in min) as per the unit definition. Volume (in milliliters) used in colorimetry determination. Volume (in milliliters) used in colorimetry determination. The difference in trypsin activity between the presence of serum and BSA demonstrated the inhibitory activity of AAT in serum. 2.4. Cystatin C inhibitory activity assay As explained before, the inhibitory activity of cystatin C was evaluated using the same principle as that of AAT. The reaction mixture (60 µL) consisted of 10 µL papain solution (1 mg/mL) (Sigma-Aldrich 76220) and 50 µL serum (diluted 100 times with ddH2O) or BSA (40 mg/mL) (diluted 100 times with ddH2O). The reaction mixtures were then incubated at 37°C for 10 min. Casein substrate (0.2%, 750 µL) (Sigma-Aldrich C-4765) was added to the tubes, and the reaction was incubated at 37°C for 10 min. Tri chloroacetic acid 0.11 M (750 µL) was then added to each vial. The reaction mixture was incubated at 37°C for 30 min to promote precipitation. The reaction mixture was centrifuged at 10,000 rpm for 15 min, and fluorescence was measured at 280 nm [23]. The inhibitory activity of cystatin C in serum is determined by the difference in papain activity between the serum and BSA. 2.5. Alpha-1 antitrypsin concentration assay The quantitative measurement of AAT in serum was performed using the Human Alpha-1 Antitrypsin ELISA Kit (SERPINA1) (ab189579, Abcam, Cambridge, UK), following the manufacturer’s recommendations. The sera had been 100,000 times diluted. Both the standards and the samples were used twice. According to reports, the serum AAT concentration was mg/dL. 2.6. Cystatin C concentration assay Cystatin C levels in serum samples were determined using the Human Cystatin C ELISA Kit (ab119589, Abcam), according to the manufacturer’s protocol. The sera were diluted at 1:100. The standards and samples were duplicated. The final cystatin C concentration was reported in mg/L. 2.7. Statistical analysis Statistical analysis was performed using SPSS version 24 (SPSS Inc., Chicago, IL, USA). The level of statistical significance was set at P ≤ 0.05. The Shapiro-Wilk test was used to test the data distribution. Levene’s test was used to examine the variance and homogeneity of the data. Normally and homogenously distributed data were analyzed using the 2-samples t test, whereas the Mann-Whitney test was performed for non-normally distributed data. 3. Results 3.1. The characteristics of subjects Participants were classified into 2 groups: patients with HDM-allergic asthma and 10 healthy subjects. The medication history of patients with asthma was recorded regardless of the dose (Table 1). Table 1.Characteristics of subjects (n = 20)Asthmatic patientsHealthy subjectsNumber of subjects1010Male/female1/93/7Age, year45.8 ± 7.339.2 ± 5.4Medication (treated/not treated)SABA3/7LABA2/8ICS/LABA8/2ICS/LABA, inhaled corticosteroid combine/long-acting beta-agonist; LABA, long-acting beta-agonist; SABA, short-acting beta agonist. Characteristics of subjects (n = 20) ICS/LABA, inhaled corticosteroid combine/long-acting beta-agonist; LABA, long-acting beta-agonist; SABA, short-acting beta agonist. 3.2. Alpha-1 antitrypsin inhibitory activity The serum AAT inhibitory activity was evaluated using casein as a substrate. Serum AAT inhibitory activity in patients with asthma was not significantly higher than that in the healthy controls (P = 0.445; Table 2). Table 2.Serum AAT inhibitory activityGroupAAT inhibitory activity (μMol/min/mL)Statistical test (t test )Asthma patients (n = 10)1.794 ± 1.154(P = 0.445)Healthy subjects (n = 10)1.389 ± 1.158AAT, alpha-1 antitrypsin. Serum AAT inhibitory activity AAT, alpha-1 antitrypsin. 3.3. Cystatin C inhibitory activity The inhibitory activity of serum cystatin C was evaluated using casein as the substrate. Serum anticysteine activity in patients with asthma was significantly higher than that in the healthy controls (P = 0.001; Table 3). Table 3.Serum cystatin C inhibitory activityGroupCystatin C inhibitory activity (μMol/min/mL)Statistical test (t test)Asthma patients (n = 10)0.260 ± 0.04(P = 0.001)*Healthy subjects (n = 10)0.190 ± 0.03*t test; the mean number of serum anticysteine activities was significantly different (P < 0.05). Serum cystatin C inhibitory activity t test; the mean number of serum anticysteine activities was significantly different (P < 0.05). 3.4. Alpha-1 antitrypsin concentration The serum AAT concentration in patients with asthma was higher than that in healthy subjects. However, the difference between the 2 groups was insignificant (P = 0.290; Table 4). Table 4.AAT concentrationGroupAAT concentration (mg/dL)Statistical test (t test)Asthma patients (n = 10)178.7 (48.3–349.3)(P = 0.290)Healthy subjects (n = 10)122.7 (49.3–315.3)AAT, alpha-1 antitrypsin. AAT concentration AAT, alpha-1 antitrypsin. 3.5. Cystatin C concentration As in AAT, the serum cystatin C levels were higher in the asthmatic subjects than in healthy subjects. The difference between the 2 groups was insignificant (P = 0.419; Table 5). Table 5.Cystatin C concentrationGroupCystatin C concentration (mg/L)Statistical test (t test)Asthma patients (n = 10)0.480 (0.276–0.850)(P = 0.419)Healthy subjects (n = 10)(0.212–0.881) Cystatin C concentration 3.6. Correlation between inhibitory activity and concentration Correlation analysis indicated positive but insignificant correlations between the concentration and activities of AAT as well as the concentration and activities of cystatin C (Tables 6 and 7). Table 6.Correlation between AAT inhibitory activity and AAT concentrationAAT inhibitory activity (μMol/min/mL)AAT concentration (mg/dL)Spearman’s rhor = 0.270 P P = 0.249; P > 0.01AAT, alpha-1 antitrypsin. Correlation between AAT inhibitory activity and AAT concentration AAT, alpha-1 antitrypsin. Table 7.Correlation between cystatin C inhibitory activity and cystatin C concentrationCystatin C inhibitory activity (μMol/min/mL)Cystatin C concentration (mg/L)Spearman’s rhor = 0.187PP = 0.429, P > 0.01 Correlation between cystatin C inhibitory activity and cystatin C concentration 4. Discussion AAT is long known as one of the acute serum phase inflammatory proteins [24]. In a cellulose acetate or agarose gel serum electrophoresis, this protein migrates in a-globulin fraction, precisely behind the albumin fraction, which is the origin of this protein’s name [25]. The protein has an antitrypsin activity and some isoforms. Deficiency or genetic variation could result in uncontrolled serine protease activities and congestive obstructive pulmonary disease or nonhepatitic, nonalcoholic liver cirrhosis [26]. Usually, AAT modulates the intrinsic serine protease enzymes, such as elastase, secreted by leukocytes during inflammation [27]. If not appropriately treated, asthma is always associated with a low degree of chronic inflammation [28]. This condition is associated with increased acute-phase proteins, including AAT, in the blood. AAT is required to counter the proteases secreted by leukocytes [29]. On the other hand, in HDM-associated asthma, the Der p 1 antigen of HMD contains digestive tract proteases of mites and serine proteases [30]. The role of AAT could be beneficial to the destructive effects of this protease. Cystatin C is an anticysteine protease [31]. These proteases are typically present in intracellular elements like calpain and cathepsins [32]. However, granulocytes and macrophages increase during inflammation, and they secrete lysosomal enzymes [33]. As in the case of AAT, cystatin C inhibits cysteine protease activities in a nonproper place [19]. In asthma patients, the role of cystatin C is to counter the cysteine protease activity in the mite antigens. We found that the AAT inhibitory activity, AAT concentration, and cystatin C concentration were not significantly higher in HDM-asthmatic patients than in healthy subjects. However, compared with healthy subjects, patients with asthma had significantly higher levels of cystatin C inhibitory activity. We also found no correlation between AAT inhibitory activity and AAT concentration or cystatin C inhibitory activity and cystatin C concentration. There was an increase in AAT inhibitory activity in HDM-asthmatic patients, although the difference was not statistically significant. The rise in AAT inhibitory activity may be an attempt to counter the serine protease-like elastase secreted by granulocytes, whose number could increase slightly in response to chronic light inflammation, which can occur in treated asthma. One study found that patients with bronchial asthma had higher levels of AAT antiprotease activity than healthy individuals, which is consistent with the results of this study [34]. Mast cells degranulate during an allergic reaction and release serine proteases such as tryptase, chymase, and carboxypeptidase A3 (CPA3). In terms of their effects on asthma, mast cell proteases are a double-edged sword. Tryptase, chymase, and CPA3 have protective functions in asthma. CPA3’s detrimental function has yet to be reported [35]. In contrast, tryptase and chymase play a role in the clinical manifestations of asthma because of their ability to provoke pro-inflammatory mediators and alarming responses and downregulate Interferons [36]. Our study also showed that cystatin C inhibitory activity was significantly higher in HDM-asthmatic patients than in healthy subjects. The increased inhibitory activity of cystatin C might be related to its role as a cysteine protease inhibitor. Cysteine proteases are known to be associated with the Der p 1 allergen, the primary allergen of HDM. It is the most potent allergen that increases the amount of Ig E [37]. As a result of the increased activity of AAT inhibition, the increased activity of cystatin C inhibition may also be considered an effort to counter the cysteine protease enzyme contained in the allergen. The results of measuring AAT concentrations in the patients with HDM-allergic asthma showed higher results of 178.7 mg/dL (48.3–349.3) compared with 122.7 mg/dL (49.3–315). The higher concentrations in the mite-allergic asthma patient group may be related to inflammatory conditions. Under inflammatory conditions, macrophages and monocytes release inflammatory mediators such as IL-1, TNF-α, and the IL-6 cytokine family, stimulating hepatocytes to produce more positive acute-phase proteins [38]. AAT is also a positive active-phase protein involved in the mechanism of inflammatory resolution [18]. The high polymorphism in the AAT-encoding gene is expressed clinically at AAT levels [39]. The wide variation in AAT concentrations in allergic asthma patients and healthy individuals may have resulted from genotypic variations rather than from diseases connected to HDM-allergic asthma. The cystatin C concentration in asthma patients is influenced by asthma treatment. Corticosteroids have been reported to elevate the serum cystatin C concentration in asthma patients significantly. A previous study in HeLa cells reported that corticosteroids induce a promoter-mediated increase in the cystatin C gene transcription [40]. Another study reported that corticosteroids significantly increased serum cystatin C levels by promoting cystatin C production in rats [41]. Shigemura et al. (2012) reported that oral corticosteroids (OCS), but not inhaled corticosteroids (ICS), significantly increased serum cystatin C levels [42]. ICS cannot stimulate the production of cystatin C might be correlated with its localized effect compared with OCS, which is a systemic effect [40]. Similar to our study, ICS did not significantly increase the serum cystatin C concentration. Eight patients with HDM-allergic asthma received the ICS/long-acting beta-agonist combination therapy. None of the patients had received OCS therapy. Another study also revealed that ICS, beta-2 agonists, or a combination of both could not increase serum cystatin C concentration [43]. The correlation test result between the AAT activity and concentration showed a weak positive correlation (r = 0.270; P = 0.249). The AAT inhibitory activity was only sometimes in line with the AAT concentration. External factors such as exposure to cigarette smoke, which causes oxidation of the active site of AAT, are known to reduce its antiprotease activity [44]. None of the participants had a history of smoking. However, passive smokers’ exposure to cigarette smoke cannot be avoided. Moreover, some isoforms of AAT have low antitrypsin activity. The correlation between cystatin C inhibitory activity and cystatin C concentration was weak (r = 0.187) and not statistically significant (P = 0.487). The inhibitory activity of cystatin C and its association with cystatin C concentration in patients with HDM-allergic asthma have not yet been reported. Currently, this phenomenon cannot be explained. However, the fact that the activities of cystatin C were significantly higher in asthma may say something, that is, the anticysteine protease activities were needed to neutralize the cysteine protease excreted by the mite. This study has some limitations, including its small sample size, cross-sectional design, lack of an inflammation marker level, lack of information on potential confounding variables that might affect the results of serum AAT and cystatin C behavior, and the absence of an allele genotype examination of AAT. In conclusion, our study demonstrated that patients with HDM-allergic asthma had significantly higher serum cystatin C inhibitory activity than healthy subjects. These results suggest that serum cystatin C activity may significantly influence the pathogenesis of HDM-allergic asthma. However, additional studies are required to elucidate the precise role of cystatin C in asthma and the mechanisms through which it contributes to the disease. Acknowledgements We thank Dr. Joedo Prihartono, M.D., MPH, for his statistical consultations of this research. This study was supported by a grant from the Republic of Indonesia’s Ministry of Research, Technology, and Higher Education/National Research and Innovation Agency (KEMENRISTEK/BRIN – PDUPT Grants Year 2021 – NKB-115/UN2 RST/HKP.05.00/2021). Conflicts of interest The authors have no financial conflicts of interest. Authors contributions Mailani Dwi Hidayati: investigation, software, and writing – original draft. Febriana Catur Iswanti and Mohamad Sadikin: funding acquisition, writing – review and editing. Samsuridjal Djauzi and Sukamto Koesn oe: resources and supervision.